A combination of immunoglobulin (IG) compositions and a soluble hyaluronidase for use to treat a disease or condition treatable with GI in a subject, wherein: GI and soluble hyaluronidase are formulated separately for subcutaneous administration； IG and soluble hyaluronidase are formulated for single dose administration once a month； soluble hyaluronidase is administered separately from the GI before administration of the GI and at the same site as the GI； the concentration of GI is 5 to 15% w / v and the amount of GI in the composition is 0.5 grams (g) to 70 g； the GI is formulated in a volume of liquid that is 50 mL to 700 mL； The soluble hyaluronidase is formulated for administration as a ratio of hyaluronidase to IG of 10 U / gram (g) at 500 U / g of IG, whereby the amount of hyaluronidase in the composition is sufficient to effect the increased bioavailability of the GI when administered in combination with GI up to at least 90% of the bioavailability of the same single dose of GI administered through intravenous administration for the treatment of the same disease or condition treatable with GI； soluble hyaluronidase is formulated in a volume of liquid that is 5 to 30 mL； and the disease or condition treatable with GI are selected from immunodeficiency； Acquired hypogammaglobulinemia secondary to hematologic malignancies； Kawasaki disease； chronic inflammatory demyelinating polyneuropathy (PDIC)； Guillain Barre syndrome； Idiopathic thrombocytopenic purpura； inflammatory myopathies； Myasthenic Lambert-Eaton syndrome； multifocal motor neuropathy； Myasthenia gravis； Moersch-Woltmann syndrome； secondary hypogammaglobulinemia, including iatrogenic immunodeficiency； specific antibody deficiency； Acute disseminated encephalomyelitis； positive systemic necrotizing vasculitis for ANCA； Autoimmune hemolytic anemia； Bullous Pemphigoid； Scarring pemphigoid； Evans syndrome, including autoimmune hemolytic anemia with immune thrombocytopenia； Feto-maternal / neonatal alloimm
